Patent · US Active

Anti-BAFFR antibody formulation

US9216219B2 · kind B2 · utility

5Cited by

0References

5Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Marta Cosenza · Basel, CH
Christoph Stark · Aalen, DE

Key dates

Filing date	Jun 7, 2013
Grant date	Dec 22, 2015
Priority date	—
Expiry date	Aug 6, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.